Business Wire

Nine-Month Figures for 2017: Sartorius Continues to Grow Profitably in a Challenging Environment

Del

Sartorius, a leading international partner of the biopharmaceutical industry and research, recorded further growth in the first nine months of 2017 despite a partly challenging business environment.

"This year, different influences shaped the business development of our divisions," commented Group CEO Dr. Joachim Kreuzburg on the results. "While our Lab Products & Services Division has continued to grow highly dynamically through organic growth and the expansion of its portfolio in the area of bioanalytics, growth of the Bioprocess Solutions Division, compared to a very high previous-year base, was somewhat lower than expected due to a few concurrent, temporary effects. However, the basic growth drivers of the global biopharma market remain intact, so that we continue to see high growth potential for our bioprocess business and confirm our mid-term targets."

Business development of the Sartorius Group

In the first nine months of 2017, Sartorius increased its sales revenue by 8.6% in constant currencies (reported: +8.1%) to 1,043.6 million euros. The Asia|Pacific region recorded the highest gain, with sales up 24.7% to 256.5 million euros. In EMEA2, Sartorius generated revenue of 451.0 million euros, 6.3% more than in the comparable year-earlier period. Especially in the Americas, transient manufacturing and supply bottlenecks in Bioprocess Solutions, as well as substantially softer customer demand for this Division after two very strong years, temporarily dampened growth dynamics. Accordingly, Group revenue in the region rose only moderately by 1.0% to 336.1 million euros. Order intake of the Sartorius Group rose at strong double-digit rates in both divisions in the third quarter and thus was up by 11.4% after nine months (all regional and order intake figures in constant currencies).

Despite unfavorable currency effects, underlying EBITDA increased by 7.3% compared with a strong prior-year base and reached 259.0 million euros. The Group's respective margin was 24.8% relative to 25.0% in the first nine months of the previous year; if exchange rates had remained constant, the prior-year figure would have been slightly exceeded. The relevant net profit3 for the Group grew by 6.9% from 98.9 million euros to 105.7 million euros. Earnings per ordinary share totaled 1.54 euros (9M 2016: 1.44 euros) and earnings per preference share 1.55 euros (9M 2016: 1.45 euros).

The Group's key financial indicators continued to remain at robust levels even after the most recent acquisitions of Essen BioScience in March 2017 and Umetrics in April 2017. At the end of the reporting period, the company's equity ratio was 33.6% and its ratio of net debt to underlying EBITDA stood at 2.7 (Dec. 31, 2016: 42.0%% and 1.5, respectively). The capex ratio in the first nine months was 13.6%, as expected, due to the comprehensive expansion of the Group's worldwide infrastructure.

Business development of the divisions

The Bioprocess Solutions Division, which offers a wide array of innovative technologies for the manufacture of biopharmaceuticals, recorded nine-month sales growth of 4.1% in constant currencies to 752.9 million euros, relative to a very high prior-year revenue base. Development in the first nine months of 2017 was somewhat lower than expected due to some temporary effects. Demand, which was relatively soft in North America and parts of Europe after two very dynamic years in 2015 and 2016, was additionally affected in the third quarter in particular by inventory destocking by a few customers. Moreover, no deliveries were meanwhile possible from the company’s production facility in Puerto Rico due to Hurricane Maria, and ongoing bottlenecks in a partner's delivery capacity that lasted longer than expected impacted business performance in the area of cell culture media. Consolidation of the acquisitions of kSep and Umetrics contributed around one percentage point to sales growth in the first nine months of 2017. Order intake grew more strongly than sales in the reporting period, by 7.1% in constant currencies due to strong double-digit growth in the third quarter.

Underlying EBITDA of Bioprocess Solutions rose by 2.2% to 207.0 million euros; the respective margin reached 27.5% relative to 27.9% for the year-earlier period and would have reached the prior-year level if currency exchange rates would have remained constant.

The Lab Products & Services Division, which offers products and technologies for laboratories primarily in the pharma sector and in public research, recorded a significant gain in revenue, up 21.8% in constant currencies (reported: +22.0%) to 290.7 million euros. Driven by strong demand in all regions and all product areas, organic growth was at a good 7%. Expansion of the division's portfolio into bioanalytics as a result of the acquisition of Essen BioScience at the end of March 2017 contributed close to 15 percentage points to growth. Order intake in the first nine months of 2017 grew by 24.9% in constant currencies.

The division's underlying EBITDA rose sharply by 34.2% to 51.9 million euros; its respective earnings margin increased, despite unfavorable currency effects, from 16.2% to 17.9%. This was due to economies of scale related to strong organic growth and to profits contributed by acquisitions.

Full-year guidance adjusted and specified; mid-term outlook confirmed

Management assumes that the previously mentioned temporary effects will influence growth of the Bioprocess Solutions Division and, along with it, that of the Sartorius Group for the full year of 2017 as well. In view of these effects, the Sartorius Group now expects that sales revenue in constant currencies will increase by approx. 9% (previous guidance: approx. 12% to 16%). Due to adverse exchange rate effects, the underlying EBITDA margin is now projected to reach approx. the prior-year level of 25.0% (previous guidance in constant currencies: slightly more than 0.5 percentage points vs. 2016).

In view of the divisions, management now expects that sales growth for Bioprocess Solutions will reach approx. 4% (previous guidance: approx. 9% to 13%) and, the underlying EBITDA margin, including adverse exchange rate effects, will be approx. at the prior-year level of 28.0% (previous guidance in constant currencies: approx. +0.5 percentage points). For Lab Products & Services, management's projections remain basically unchanged, with sales expected to grow by about 22% (previous bandwidth 20% to 24%) and the division's underlying EBITDA margin forecasted to increase by nearly two percentage points relative to 16.0% a year ago, despite unfavorable currency effects.

The capex ratio for the current year is projected to be at the upper end of the bandwidth of around 12% to 15% of sales.

Sartorius confirms its mid-term targets.

1 Sartorius uses underlying EBITDA (earnings before interest, taxes, depreciation and amortization and adjusted for extraordinary items) as the key profitability indicator

2 EMEA = Europe | Middle East | Africa

3 After non-controlling interest, adjusted for extraordinary items and non-cash amortization, as well as based on the normalized financial result and corresponding tax effects

This earnings release contains statements about the future development of the Sartorius Group. The content of these statements cannot be guaranteed as they are based on assumptions and estimates that harbor certain risks and uncertainties. The content of these statements cannot be guaranteed as they are based on assumptions and estimates that harbor certain risks and uncertainties.

Current image files

Dr. Joachim Kreuzburg, CEO and Executive Board Chairman of Sartorius AG

www.sartorius.com/fileadmin/media/global/company/Sartorius_Kreuzburg.jpg

Sartorius products used in the manufacture of medications

www.sartorius.com/mediafile/corp/Sartorius_0232_PG9_01_RGB.jpg

Sartorius products used in pharmaceutical research

www.sartorius.com/mediafile/corp/Sartorius_0424_PG14.jpg

Conference call

Dr. Joachim Kreuzburg, CEO and Executive Board Chairman of Sartorius, will discuss the company's results with analysts and investors on Wednesday, October 25, 2017, at 3:30 p.m. Central European Time (CET) in a teleconference. You may register by clicking on the following link:

http://services.choruscall.de/DiamondPassRegistration/register?confirmationNumber=8481620&linkSecurityString=2746420dc

Alternatively, you can dial into the teleconference, without registering, at:

+49 (0) 69 566 03 6000

To view the presentation, log onto:

http://www.sartorius.com/com/group/investor-relations/sartorius-ag/

Upcoming financial dates

February 6, 2018 Publication of preliminary figures for 2017

A Profile of Sartorius

The Sartorius Group is a leading international pharmaceutical and laboratory equipment provider with two divisions: Bioprocess Solutions and Lab Products & Services. Bioprocess Solutions with its broad product portfolio focusing on single-use solutions helps customers produce biotech medications and vaccines safely and efficiently. Lab Products & Services, with its premium laboratory instruments, consumables and services, concentrates on serving the needs of laboratories performing research and quality assurance at pharma and biopharma companies and on those of academic research institutes. Founded in 1870, the company earned sales revenue of more than 1.3 billion euros in 2016. Currently more than 7,400 people work at the Group's 50 manufacturing and sales sites, serving customers around the globe.

Key Performance Indicators for the 9-Month Period of 2017

 

Sartorius Group

  Bioprocess Solutions   Lab Products & Services

€ in millions

                         
(unless

Δ in

Δ in

Δ in

otherwise

9M

9M

%

Δ in

9M 9M

%

Δ in

9M 9M

%

Δ in

specified)  

2017

 

2016

 

reported

 

% cc(1)

 

2017

      2016   reported  

% cc(1)

  2017       2016   reported  

% cc(1)

Sales Revenue and Order Intake                                                        
Sales revenue   1043.6   965.1   8.1   8.6   752.9       726.7   3.6   4.1   290.7       238.4   22.0   21.8
- EMEA2   451.0   427.1   5.6   6.3   310.3       306.9   1.1   2.1   140.7       120.2   17.1   16.9
- Americas2   336.1   331.4   1.4   1.0   263.7       279.5   -5.7   -6.0   72.5       51.9   39.6   38.2
- Asia | Pacific2   256.5   206.6   24.2   24.7   178.9       140.3   27.5   27.8   77.6       66.3   17.1   18.2
Order intake   1096.4   988.2   11.0   11.4   802.0       752.5   6.6   7.1   294.4       235.6   24.9   24.9
Earnings                                                        
EBITDA3   259.0   241.4   7.3       207.0       202.6   2.2       51.9       38.7   34.2    
EBITDA margin3 in %   24.8   25.0           27.5       27.9           17.9       16.2        
Net profit for the period4   105.7   98.9   6.9                                            
Financial Data per Share                                                        
Earnings per ordinary share4 in €   1.54   1.44   6.9                                            
Earnings per preference share4 in €   1.55   1.45   6.8                                            
1 In constant currencies abbreviated as "cc"
2 Acc. to the customer's location
3 Underlying
4 After non-controlling interest, adjusted for extraordinary items and non-cash amortization, as well as based on the normalized financial result and
corresponding tax effects

Contact information

Sartorius AG
Petra Kirchhoff
Vice President of Corporate Communications
+49 (0)551.308.1686
petra.kirchhoff@sartorius.com
or
Andreas Theisen
Director of Investor Relations
+49 (0)551.308.1668
andreas.theisen@sartorius.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Manchester United and True Religion Launch Denim Range19.10.2018 17:37Pressemelding

Manchester United (NYSE:MANU) and luxury denim brand True Religion have collaborated to launch a range of premium club branded denim wear. A first for the club, the new global partnership with the iconic American denim brand will see a range of men’s & women’s co-branded styles go on sale beginning 26th October in the club’s Megastore as well as online via United Direct and truereligion.com & eu.truereligion.com. The exclusive collection features jeans, shirts and jackets, including a highly desirable limited edition denim jacket embroidered with the club’s crest. Fans will have the opportunity to win a selection of clothing from the new range by visiting www.manutd.com/truereligion. Manchester United’s Group Managing Director, Richard Arnold, comments: “True Religion is a well-known, established name in fashion, creating unique designs without compromising on quality. The range we have collaborated on includes the same attention to detail and craftsmanship that has made True Religion

Arch Insurance Announces Strategic Leadership Changes19.10.2018 13:10Pressemelding

Arch Insurance today announced that Matt Shulman will assume the newly created role of CEO, Arch Insurance North America, effective January 1, 2019. In this role, he will lead Arch Insurance’s operations in the United States and Canada. He will report to Nicolas Papadopoulo, Chairman and CEO of Arch Worldwide Insurance Group. Mr. Shulman, who has more than 20 years of experience in the insurance industry, has been with Arch Insurance since 2009 and has served as the President and CEO of Arch Insurance Europe since 2016. “Matt brings significant U.S. and international experience to this role. Under his leadership, together with our senior team, Arch Insurance will continue to enhance our value proposition to our customers through a robust, diversified product portfolio, creative solutions and excellent service,” Mr. Papadopoulo said. Arch Insurance has also created a new organizational structure with three Chief Underwriting Officers (CUO) dedicated to specific lines of business. These

Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer19.10.2018 12:00Pressemelding

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1 st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients. Data for these secondary endpoints will be presented in a poster discussion at the European Society for Medical Oncology (ESMO) 2018 Congress on Friday, October 19 at 2:00 p.m. CET in Munich, Germany. These results further support ALUNBRIG as a potential treatment for adults with ALK+ locally advanced or metastatic NSCLC who had not received a prior ALK inhibitor. ALUNBRIG is currently not approved as first-line therapy for advanced ALK+ NSCLC. “ALK+ NSCLC often spreads to the brain, so having options that can clearly demonstrate efficacy both in the brain an

Vertex Receives European CHMP Positive Opinion for KALYDECO® (ivacaftor) to Treat Patients With Cystic Fibrosis Aged 12 to <24 months With Certain Mutations in the CFTR Gene19.10.2018 11:54Pressemelding

Vertex Pharmaceuticals (Europe) Limited today announces that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for KALYDECO® (ivacaftor) to include the treatment of people with cystic fibrosis (CF) aged 12 to <24 months who have at least one of the following nine mutations in their cystic fibrosis transmembrane conductance regulator (CFTR) gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. If the European Commission issues a favorable adoption of the EMA CHMP opinion for the extension of indication, ivacaftor will be the first and only medicine approved in Europe to treat the underlying cause of CF in patients aged 12 to <24 months, who have specific mutations in the CFTR gene. “Cystic fibrosis is a chronic, progressive disease that is present at birth, with symptoms often occurring in infancy, so early treatment is crucial to deliver the best possible outcomes for patients,” said Reshma Kewalr

Schlumberger Announces Third-Quarter 2018 Results19.10.2018 11:00Pressemelding

Schlumberger Limited (NYSE: SLB) today reported results for the third quarter of 2018. (Stated in millions, except per share amounts) Three Months Ended Change Sept. 30, 2018 Jun. 30, 2018 Sept. 30, 2017 Sequential Year-on-year Revenue $8,504 $8,303 $7,905 2% 8% Pretax operating income $1,152 $1,094 $1,059 5% 9% Pretax operating margin 13.5% 13.2% 13.4% 36 bps 15 bps Net income - GAAP basis $644 $430 $545 50% 18% Net income, excluding charges & credits* $644 $594 $581 8% 11% Diluted EPS - GAAP basis $0.46 $0.31 $0.39 48% 18% Diluted EPS, excluding charges & credits* $0.46 $0.43 $0.42 7% 10% North America revenue $3,189 $3,139 $2,602 2% 23% International revenue $5,215 $5,065 $5,147 3% 1% North America revenue, excluding Cameron $2,572 $2,546 $2,086 1% 23% International revenue, excluding Cameron $4,559 $4,387 $4,430 4% 3% *These are non-GAAP financial measures. See section below entitled "Charges & Credits" for details. Schlumberger Chairman and CEO Paal Kibsgaard commented, “Our third

Tradeshift Announces Q3 2018 Results19.10.2018 11:00Pressemelding

Tradeshift, the leader in supply chain payments and marketplaces, today announced results from the third quarter of 2018, marking the tenth quarter in a row of successive growth and beating targets. Tradeshift’s third quarter growth stats announced today include: YoY revenue grew 400 percent (trailing 12 months) YoY new bookings grew 284 percent YoY gross merchandise volume (GMV) grew 262 percent New total contract value grew by $47M in Q3 Tradeshift’s customer roster continued strong growth this quarter adding 27 new customers, including Hertz, Shiseido, ECU, and Fortune 500 leaders in retail apparel, agriculture, engineering and construction, hospitality, travel and food delivery. Tradeshift also expanded its app ecosystem by adding a key partnership with Coface, a global credit insurer. Coface has announced a new app solution on the Tradeshift platform offering risk and business information services to help businesses make decisions by ensuring greater financial transparency between